General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Takeda
- 12 Jul 2024 Planned End Date changed from 31 May 2026 to 30 Nov 2027.
- 12 Jul 2024 Planned primary completion date changed from 31 May 2026 to 30 Nov 2027.
- 03 Nov 2021 New trial record